

3-2-04

1614
\$

CASE 4-30602B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 365588646 US

Express Mail Label Number

March 1, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

DE BRUIJN ET AL.

Examiner: Delacroix Muirhei, Cybille

APPLICATION NO: 10/620,178

FILED: JULY 15, 2003

FOR: NEW ORAL FORMULATION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced application, please amend the application as follows:

Amendments to the claims begin on page 2.

Remarks/Arguments begin on page 5 of this paper.

03/05/2004 BABRAHA1 00000095 190134 10620178

01 FC:1202 108.00 DA



CASE 4-30602B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 365588646 US

Express Mail Label Number

3/1/04

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

DE BRUIJN ET AL.

Examiner: Delacroix Muirhei, Cybille

APPLICATION NO: 10/620,178

FILED: JULY 15, 2003

FOR: NEW ORAL FORMULATION

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE FOR ADDITIONAL CLAIMS

Sir:

Filing fee calculation:

- ☒ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.
☐ Before calculating the filing fee, please cancel claims

Basic Filing Fee							\$	0
Multiple Dependent Claim Fee (\$ 290)							\$	
Foreign Language Surcharge (\$ 900)							\$	
	For	Number Filed		Number Extra		Rate		
Extra Claims	Total Claims	26	-20	6	x	\$ 18	=	\$ 108
	Independent Claims	3	-3	0	x	\$ 86	=	\$
TOTAL FILING FEE							\$	108


- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$878. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (973) 781-8064.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "David E. Wildman", written over a horizontal line.

David E. Wildman
Attorney for Applicants
Reg. No. 40,226
Tel. No. (862) 778-7954

Date: 3/1/04